R2therapies Oy

R2therapies Oy

R2therapies Oy has discovered a novel and scientifically surprising blood-based biomarker to identify people at risk of developing dementia. The company aims to to develop an in-vitro diagnostic method compatible with primary healthcare for dementia-risk screening....
AarogyaAI

AarogyaAI

AarogyaAI’s vision is to make precision diagnosis for antimicrobial resistance accessible at the point of care by harnessing the powers of genomics and artificial intelligence. The aim is to reduce the incidence and spread of antimicrobial-resistant infections and...
CorFlux

CorFlux

CorFlux aims to be the world’s leading analyzing software for estimating the risk of aortic aneurysm rupture. The current clinical method does not take into account other influencing elements than the aortic diameter in the risk evaluation. However, a high number of...
NADMED Oy

NADMED Oy

The biology and key role of NAD molecules in human metabolism has been well known for decades, but measuring them has been devilishly difficult. NADMED has now brought to market an accurate, fast, scalable, and well protected method to do just that. The assay enables...

Probiont Oy

Probiont is developing personalized solutions for cancer immunotherapy efficacy testing. Our technology is purposed to enable rapid screening of cancer drugs used in immunotherapy, for early identification of effective treatment strategies for individual patients....